Late last month, the U.S. Health Resources and Services Administration (HRSA) said on its website that generic drug manufacturer Unichem Pharmaceuticals USA had to repay 340B covered entities for overcharges found during a 340B program compliance audit.
According to Unichem, the audit found it overcharged only two entities and the repayment to both totals just $110.20. “Unichem cooperated fully with the audit process and is refunding those two facilities,” the company said. It said its audit covered six months of 340B ceiling price calculations and 340B pricing offered to over 11,100 eligible facilities.
Generic drug manufacturer Unichem says a 340B compliance audit found it overcharged only two entities and the repayment to both totals just $110.20.
Please Login or Become a Paid Subscriber to View this Content
If you are already a paid subscriber, please follow the steps below.
